Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Liver cancer drugs market size to grow by USD 5.29 billion from 2021 to 2026: A descriptive analysis of customer landscape, vendor assessment, and market dynamics - Technavio


NEW YORK, Feb. 8, 2023 /PRNewswire/ -- The global liver cancer drugs market size is estimated to increase by USD 5.29 billion from 2021 to 2026. The market's growth momentum will accelerate at a CAGR of 14.67%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Discover some insights on the market size before buying the full report -Request a sample report

Liver cancer drugs market - Customer Landscape
To help companies evaluate and develop growth strategies, the report outlines ?

Liver cancer drugs market ? Vendor analysis
Vendor offerings -

Vendor landscape ?

The global liver cancer drugs market is fragmented, with the presence of several vendors. A few prominent vendors that offer liver cancer drugs in the market are Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Q BioMed Inc. and others.

The vendors are deploying growth strategies such as acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share. Large vendors are acquiring and forming mergers with other vendors to expand their portfolio of offerings and increase their market share. Vendors are also focusing on improving their profitability. These factors are expected to further intensify the completion in the market during the forecast period.

Liver cancer drugs market - Segmentation assessment

Segment overview
Technavio has segmented the market based on type (immunotherapy and targeted therapy).

Geography overview
Based on geography, the global liver cancer drugs market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global liver cancer drugs market.

Download a sample report

Liver cancer drugs market ? Market dynamics

Leading drivers - The increasing incidence of liver cancer is driving the growth of the market. The risk of liver cancer depends on the etiology. Hepatitis B and C and underlying cirrhosis are the main risk factors. In the US, hepatitis C is present in more than half of the patients with certain liver cancers. Fatty liver is a major cause of liver cancer in the US, followed by hepatitis C. Long-term alcohol consumption can also increase the incidence of liver cancer. Moreover, diabetes, obesity, and related non-alcoholic fatty liver disease can also be associated with an increase in the incidence of liver cancer. These factors will drive the market growth during the forecast period.

Key trends - The use of mABs is a key trend in the market. The use of monoclonal antibody (mAB) therapies is a new approach to treating liver cancer. Research is also being conducted to develop high-stability and high-affinity antibodies and fragments, which can target tumor-specific antigens in liver cancer. Monoclonal antibodies are sensitive and can create a level of specificity that reduces the chances of side effects. In addition, they are highly stable. These factors will support market growth during the forecast period.

Major challenges Surgical resection and transplantation being the only curative option will challenge the liver cancer drugs market during the forecast period. The treatment of liver cancer is based on the stage of the disease and the functioning of the organ. However, disease-modifying drugs are unavailable, which makes surgical treatment the only recommended option. However, surgery is often associated with a high recurrence rate of tumors. These factors will hinder the growth of the market during the forecast period.

Drivers, trends, and challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report!

What are the key data covered in this liver cancer drugs market report?

Gain instant access to 17,000+ market research reports. 

Technavio's SUBSCRIPTION platform

Related Reports:

The breast cancer therapeutics market size is expected to increase by USD 13.85 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.95%. This report extensively covers segmentation by product (targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

The colorectal cancer therapeutics market size is expected to increase by USD 2.45 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.43%. This report extensively covers segmentation by type (targeted therapy, immunotherapy, and chemotherapy) and geography (North America, Europe, Asia, and Rest of World (ROW)).

Liver Cancer Drugs Market Scope

Report Coverage

Details

Page number

120

Base year

2021

Historic period

2017-2021

Forecast period

2022-2026

Growth momentum & CAGR

Accelerate at a CAGR of 14.67%

Market growth 2022-2026

USD 5.29 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

10.4

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 42%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading vendors, market positioning of vendors, competitive strategies, and industry risks

Key companies profiled

Alnylam Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol-Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., Eureka Therapeutics, Exelixis Inc., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Lion TCR Pte. Ltd, Merck and Co. Inc., Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., and Q BioMed Inc.

Market dynamics

Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse for Technavio's health care market reports

Table of contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Five Forces Analysis

5 Market Segmentation by Type

6 Customer Landscape

7 Geographic Landscape

8 Drivers, Challenges, and Trends

9 Vendor Landscape

10 Vendor Analysis

11 Appendix

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
Newsroom: https://newsroom.technavio.org/news/liver-cancer-drugsmarket

SOURCE Technavio


These press releases may also interest you

at 09:48
Perspire Sauna Studio, one of the country's largest sauna franchises specializing in full spectrum infrared (IR) and red-light therapy (RLT), is rolling out a new sauna design and member experience through the brand's long-standing partnership with...

at 09:38
The Kinetix Group (TKG) and Pfizer Inflammation and Immunology received a PM360 Pharma Choice Award for their recent health equity initiative. The award recognized Pfizer's atopic dermatitis interactive guide for varying skin tones....

at 09:37
Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China and the United States, today announced it has been granted a new Class III certificate by the National...

at 09:15
101 Mobility® is thrilled to announce the opening of its newest location in Eden Prairie, marking the introduction of the city's first nationally branded full-service provider of a wide range of mobility equipment. This includes stair lifts, ramps,...

at 09:15
Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health.This approval enables Vibrant...

at 09:07
Olympus announced today that it has been awarded a contract for its advanced energy portfolio by Provista Inc. This new, nationwide agreement provides Provista members with negotiated pricing for Olympus® energy products, including the...



News published on and distributed by: